Sotac Pharmaceuticals

Sotac Pharmaceuticals Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 27, 2026 is -1.94. In the previous year, Net Debt to Free Cash Flow Ratio was -0.63 — a change of 206.21% (lower).

Net Debt/FCF

-1.94

YoY

206.21%

Last updated:

Net Debt to Free Cash Flow Ratio of Sotac Pharmaceuticals is 2025 -1.94 . Net Debt to Free Cash Flow Ratio of Sotac Pharmaceuticals was 2024 -0.63 . It decreases by 206.21% lower compared to the previous year.

The Sotac Pharmaceuticals Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2020
-1.32 INR
Jan 1, 2021
-4.81 INR
Jan 1, 2022
2.59 INR
Jan 1, 2024
-0.63 INR
Jan 1, 2025
-1.94 INR
The Sotac Pharmaceuticals Net Debt/FCF history
YEARNet Debt/FCFYoY
-1.94+206.21%
-0.63-124.52%
2.59-153.72%
-4.81+264.75%
-1.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Net Debt to Free Cash Flow Ratio of Sotac Pharmaceuticals is -1.94 in 2025.

Net Debt to Free Cash Flow Ratio of Sotac Pharmaceuticals changed from -0.63 to -1.94, representing a 206.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Sotac Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals